| Literature DB >> 32251469 |
Luca Ponzoni1, Nga H Nguyen2, Ivet Bahar1, Jeffrey L Brodsky2.
Abstract
The renal outer medullary potassium (ROMK) channel is essential for potassium transport in the kidney, and its dysfunction is associated with a salt-wasting disorder known as Bartter syndrome. Despite its physiological significance, we lack a mechanistic understanding of the molecular defects in ROMK underlying most Bartter syndrome-associated mutations. To this end, we employed a ROMK-dependent yeast growth assay and tested single amino acid variants selected by a series of computational tools representative of different approaches to predict each variants' pathogenicity. In one approach, we used in silico saturation mutagenesis, i.e. the scanning of all possible single amino acid substitutions at all sequence positions to estimate their impact on function, and then employed a new machine learning classifier known as Rhapsody. We also used two additional tools, EVmutation and Polyphen-2, which permitted us to make consensus predictions on the pathogenicity of single amino acid variants in ROMK. Experimental tests performed for selected mutants in different classes validated the vast majority of our predictions and provided insights into variants implicated in ROMK dysfunction. On a broader scope, our analysis suggests that consolidation of data from complementary computational approaches provides an improved and facile method to predict the severity of an amino acid substitution and may help accelerate the identification of disease-causing mutations in any protein.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32251469 PMCID: PMC7162551 DOI: 10.1371/journal.pcbi.1007749
Source DB: PubMed Journal: PLoS Comput Biol ISSN: 1553-734X Impact factor: 4.475
Fig 3Scatter plots comparing computational predictions and identifying consensus and discordant data.
The two scatter plots compare the predictions from Rhapsody and EVmutation (left) and those from Rhapsody and PolyPhen-2 (right), allowing the outputs to be grouped in three different categories: consensus neutral, consensus deleterious, and discordant, as indicated by the labels. Cutoff values between neutral/deleterious predictions for each method are represented by dashed lines. Note that EVmutation’s ΔE score anticorrelates with the expected pathogenicity of variants. The 31 variants selected for experimental validation and two controls (see text, and ) are labelled in the two plots and marked by different symbols and colors based on the experimentally observed phenotypes. Results for those variants which cannot be evaluated using EVmutation, due to the absence of a suitable Pfam domain and/or MSA, are shown in the right plot only, with abscissa values based on PolyPhen-2 scores. Labels written in square brackets refer to rat ROMK1 variants that were experimentally tested after substituting for the counterparts in the human sequence.
Fig 5Growth phenotypes of trk1Δtrk2Δ yeast expressing the ROMK1 variants.
Representative yeast viability assays with control strains and the ROMK1 variants in group 6 were performed on (A) solid and (B) liquid medium. (A) Ten-fold dilutions of overnight, saturated cultures of yeast were inoculated on medium as described in . Images were taken after two days of incubation at 30°C. (B) Saturated yeast cultures were diluted to a starting OD600 of 0.2 with assay medium supplemented with 25mM KCl and grown at 30°C. OD600 readings were recorded and data were standardized as described in the Materials and Methods and in . Data represent results from two independent experiments (n = 2–3 each), ± the range of the data. (C) Table summarizing the growth phenotypes of the six ROMK1 groups described in the text. The predicted consequence of each group is denoted. Growth phenotypes were obtained in a blinded fashion, compared to the growth of trk1Δ trk2Δ yeast expressing WT ROMK1, and the results are color-coded: Red denotes a severe growth defect, orange denotes a moderate growth defect, green denotes no growth defect (WT-like), and blue denotes a slight increase in growth compared to the WT control. These classifications were performed by visual inspection. For example, as shown in , the P265R variant exhibited levels of growth that matched the vector control (i.e., the errors overlapped in ), and hence this mutation was designated “severe growth defect” in part (C). In contrast, the P265Y variant exhibited levels of growth that were intermediate to that of the vector control and “Wild-type” (). Hence, this mutation was designated “moderate growth defect” in part (C).
List of known mutations associated with Bartter syndrome and their computationally predicted classification.
| mutation | comp. prediction | mutation | comp. prediction |
|---|---|---|---|
| C49Y | R188C | ||
| I51T | R188H | ||
| T71M | A198T | ||
| V72E | L209F | ||
| D74Y | A214V | ||
| Y79H | neutral | S219R | |
| T86A* | neutral* | L220F | |
| F95S | G228E | ||
| K107E | neutral | A306T | |
| D108H | R311W | ||
| V122E | S313C | ||
| N124K | Y314C | ||
| I142T | L320P | ||
| A156V | R324L | neutral | |
| G167E | F325C | ||
| A177T | P327L | ||
| P185S | M357T* | neutral* |
Amino acid coordinates are numbered according to their position in human ROMK1. Correct predictions are highlighted in red boldface. Out of 34 SAVs reported in the literature to be associated with Bartter syndrome, 29 are correctly predicted by Rhapsody to be deleterious, while 5 are predicted to be neutral. In this group, two variants (T86A and M357T, marked by *) are classified as benign or likely benign in the human clinical variant database. See Materials and Methods for further details. For a distribution of the predicted scores, refer to S5 Fig.